 The U.S. Food and Drug Administration FDA sent a communication to Reata Pharmaceuticals Inc. NASDAQ: RETA on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharmaceutical companys shares gained 20 in the morning session. 